Stock Analysts Maintain Optimism for Gossamer Bio Wedbush has reiterated its "outperform" rating for Gossamer Bio, setting a $4.00 target price, reflecting a potential 175.86% upside. Analysts highlight the company's robust pipeline, especially the ongoing Phase 3 trials for seralutinib, and its strong financial position as key factors supporting positive sentiment.3